Reductionist Science and the Evolution of Integrative Oncology
By Glenn Sabin
The placebo-controlled, double-blind, randomized controlled trial (RCT) is considered the most reliable scientific process to measure safety and efficaciousness of drugs and medical interventions. The RCT measures one variable or intervention at a time against a control.
On February 25-27, 2009, the Institute of Medicine, with support from the Bravewell Collaborative, convened the Summit on Integrative Medicine and the Health of the Public in Washington, DC. The stated goal of the conference was to advance the science, understanding, and progress of integrative medicine—“healthcare that addresses together the mental, emotional, and physical aspects of the healing process”. IOM released its report on the summit last month. The following passage from the report speaks to reductionism science and its impact on the exploration of integrative interventions:
“Integrative health care is derived from lessons integrated across scientific disciplines, and it requires scientific processes that cross domains. The most important influences on health, for individuals and society, are not the factors at play within any single domain—genetics, behavior, social or economic circumstances, physical environment, health care—but the dynamics and synergies across domains. Research tends to examine these influences in isolation, which can distort interpretation of the results and hinder application of results. The most value will come from broader, systems-level approaches and redesign of research strategies and methodologies.”
The human mind and body, when confronted with malignancy, reacts with a complex set of physiological and psychological change that cannot be adequately addressed in isolation. As such, only whole person, multi-interventional research models will lead the way to 21st century truly personalized, integrative oncology care.
Millions of dollars have been expended on studies focusing on one variable against a control. Historically, this has been the only type of study design that has passed NIH’s research funding review boards. NCCAM and OCCAM have funded a number of single-modality studies over the years that follow these reductionistic standards of medical exploration. In fact, NIH has heretofore never funded research that explores more than one type of intervention at a time. There have been studies that have focused on multivitamins, vitamin E, calcium, acupuncture, exercise and many other single agents or interventions, but no complex, multiple modality trial designs have been funded or executed to date. Notably, Dr. Dean Ornish published positive outcomes on his seminal work in the areas of cardiac health and prostate cancer. There has been no significant research on truly comprehensive lifestyle interventions in malignancy since.
The time is now for the federal government, private entities, organizations and philanthropists to support and fund comprehensive, whole systems medical research.
There are creative ways to approach whole systems, integrative oncology study designs in such a way that they will pass government and private funding review boards as well as research ethics review committees, but it requires fresh, innovative thinking and very creative and committed research teams.
Random controlled trials are here to stay, and rightfully so, but a lot has changed since the Flexner Report. Personalized medicine is growing and evolving: over 30 billion dollars annually are being spent in the U.S. on complementary health services and products, and consumers are embracing integrative healthcare practitioners like never before. In addition to the RCT, we need a human clinical trial research model specifically designed for whole systems research.
The best of western, allopathic medicine, especially acute emergency care and diagnostics, is arguably the finest in the world. But it is clear that our so-called science-based processes and methodologies that result in FDA approved drugs do not always allow the most useful and important study designs in integrative medicine to be funded and executed.
Now is the time for the U.S. to institute a new research design paradigm that addresses the whole person, body and mind, with a synergistic, multi-interventional approach. We are on the cusp of true personalized, integrative healthcare/oncology, and we will get there a lot faster once whole system research is properly funded and executed.
FON: The Business of Integrative Health + Medicine
30-MIN COMPLIMENTARY BUSINESS